更新于：2024-07-01
Denenicokin
更新于：2024-07-01
概要
基本信息
在研机构- |
最高研发阶段终止临床2期 |
首次获批日期- |
最高研发阶段(中国)- |
特殊审评- |
序列信息
Sequence Code 48174
来源: *****
关联
10
项与 Denenicokin 相关的临床试验A Phase 1 Dose Escalation Study of BMS-982470 (Recombinant Interleukin-21, rIL-21) in Combination With BMS-936558 (Anti-PD-1) in Subjects With Advanced or Metastatic Solid Tumors
A Phase I Dose Escalation Study of BMS-982470 (Recombinant Interleukin 21, rIL-21) in Combination With Ipilimumab in Subjects With Unresectable Stage III or Stage IV Melanoma
A Randomized Phase II Study of Interleukin-21 (rIL-21) Versus Dacarbazine (DTIC) in Patients With Metastatic or Recurrent Melanoma
100 项与 Denenicokin 相关的临床结果
登录后查看更多信息
100 项与 Denenicokin 相关的转化医学
登录后查看更多信息
100 项与 Denenicokin 相关的专利（医药）
登录后查看更多信息
303
项与 Denenicokin 相关的文献（医药）2024-01-01International immunopharmacology
Biological effects of IL-21 on immune cells and its potential for cancer treatment
Review
作者: Qin, Xiaosong ; Liu, Jianhua ; Liu, Yong ; Wu, Lina ; Xie, Yuanyuan ; Ma, Meichen
Interleukin-21 (IL-21), a member of the IL-2 cytokine family, is one of the most important effector and messenger molecules in the immune system. Produced by various immune cells, IL-21 has pleiotropic effects on innate and adaptive immune responses via regulation of natural killer, T, and B cells. An anti-tumor role of IL-21 has also been reported in the literature, as it may support cell proliferation or on the contrary induce growth arrest or apoptosis of the tumor cell. Anti-tumor effect of IL-21 enhances when combined with other agents that target tumor cells, immune regulatory circuits, or other immune-enhancing molecules. Therefore, understanding the biology of IL-21 in the tumor microenvironment (TME) and reducing its systemic toxic and side effects is crucial to ensure the maximum benefits of anti-tumor treatment strategies. In this review, we provide a comprehensive overview on the biological functions, roles in tumors, and the recent advances in preclinical and clinical research of IL-21 in tumor immunotherapy.
2023-11-26Journal of drug targeting
Enhanced chemoimmunotherapy of breast cancer in mice by apolipoprotein A1-modified doxorubicin liposomes combined with interleukin-21
Article
作者: Guo, Xiaohan ; Wang, Rui ; Feng, Meiqing ; Liu, Hongchuan ; Chen, Nanye ; He, Peng ; Li, Xiang ; Yu, Xiaochen ; An, Duopeng
Backgroud: Breast cancer is a prevalent malignancy among women, with triple-negative breast cancer (TNBC) comprising approximately 15-20% of all cases, possessing high invasiveness, drug resistance and poor prognosis. Chemotherapy, the main treatment for TNBC, is limited by toxicity and drug resistance. Apolipoprotein A1 modified doxorubicin liposome (ApoA1-lip/Dox) was constructed in our previous study, with promising anti-tumour effect and improved safety been proved. However, during long-term administration, the problem of cumulative toxicity and insufficient tumour inhibition is still inevitable. Interleukin-21 is a small molecule protein secreted by T cells with various immune regulatory functions. IL-21 has significantly curative effects in numerous solid tumours, but it has the disadvantages of low response rate and short half-life. The combination of chemotherapy and immunotherapy has received increasing attention.Purpose: In this study, ApoA1 drug loading system and long-acting IL-21 are innovatively combined for tumour treatment.Methods: We combined ApoA1-lip/Dox and IL-21 for treatment and evaluated their impact on tumor-infiltrating lymphocytes and CD8+ T and NK cell cytotoxicity.Results: Combined administration significantly improved the tumour-infiltrating lymphocytes and enhanced the cytotoxicity of CD8+ T and NK cells. The combination of ApoA1-lip/Dox and IL-21 exhibits significantly enhanced anti-tumour efficacy with lower toxicity of ApoA1-lip/Dox, providing a new strategy for TNBC treatment with enhanced anti-tumour response and reduced toxicity.
2023-09-01Journal of medicine and life
Cut-off values for IL-21 and IL-23 as biochemical markers for pemphigus vulgaris.
Article
作者: Al-Hasnawi, Zahra Ali ; Al-Drobie, Ban
Pemphigus vulgaris (PV) is a potentially fatal mucocutaneous autoimmune disease characterized by severe skin lesions. Interleukin-21 (IL-21) and IL-23 have been linked to several autoimmune inflammatory diseases that may have a critical role in PV immunopathogenesis, including T-helper 17 (Th17) development. This study aimed to compare the serum levels of IL-21 and IL-23 in patients with PV and healthy controls. This case-control study included 90 participants (45 patients and 45 controls). Serum IL-21 and IL-23 were measured using the Sandwich-ELISA method provided by Sunlong Biotech, China. The findings revealed statistically significant results for IL-21 O.D. and Conc. (p=0.012*) and highly significant results for IL-23 O.D. and Conc. (p=0.000**). Furthermore, cut-off values were established for IL-21 (O.D.=0.071 pg/mL, Conc.=6.468 pg/mL) and IL-23 (O.D.=0.141 pg/mL, Conc.=6.745 pg/mL). These results indicate a potential association between PV and IL-21, IL-23, and the identified cut-off values. The particular roles of cytokines and how they can be utilized to treat PV require more investigation. To our knowledge, this was the first study to detect a cut-off point for IL-21 and IL-23 that may be used as novel and cost-effective biochemical markers for disease diagnosis.
34
项与 Denenicokin 相关的新闻（医药）2024-05-10
·今日头条
临床结果临床研究
2024-04-22
·今日头条
细胞疗法临床结果临床研究
2024-03-26
临床结果临床3期细胞疗法上市批准临床2期
100 项与 Denenicokin 相关的药物交易
登录后查看更多信息
研发状态
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 复发性黑色素瘤 | 临床2期 | 加拿大 | 2007-12-13 | |
| 皮肤黑色素瘤 | 临床2期 | 加拿大 | 2007-12-13 | |
| 卵巢癌 | 临床2期 | 法国 | 2007-10-04 | |
| 卵巢癌 | 临床2期 | 德国 | 2007-10-04 | |
| 肾细胞癌 | 临床2期 | 德国 | 2007-07-12 | |
| 肾细胞癌 | 临床2期 | 荷兰 | 2007-07-12 | |
| 恶性黑色素瘤IV期 | 临床2期 | 澳大利亚 | 2004-09-01 | |
| 转移性黑色素瘤 | 临床2期 | 澳大利亚 | 2004-09-01 | |
| 不可切除的黑色素瘤 | 临床1期 | 美国 | 2011-12-01 | |
| 不可切除的黑色素瘤 | 临床1期 | 波多黎各 | 2011-12-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | - | 15 | 觸鏇顧鑰艱鑰壓構鏇壓(壓壓蓋願鏇積繭鏇鬱繭) = 鬱積餘醖願選鏇夢膚網 鏇顧遞選憲餘齋壓衊夢 (鑰積廠夢窪壓選製蓋淵 ) | - | 2017-01-01 | ||
ART-only controls | 觸鏇顧鑰艱鑰壓構鏇壓(壓壓蓋願鏇積繭鏇鬱繭) = 窪鑰壓鹹鏇簾齋繭蓋鹹 鏇顧遞選憲餘齋壓衊夢 (鑰積廠夢窪壓選製蓋淵 ) | ||||||
N/A | - | 觸鬱膚遞網鏇顧鏇窪築(範繭鏇鏇願構選憲遞齋) = 憲蓋淵鑰築觸範憲淵鬱 醖鬱願蓋齋餘糧醖壓鑰 (齋膚觸獵蓋鏇遞選選蓋, 0.09) 更多 | - | 2015-11-10 | |||
網醖願簾製醖淵鬱鑰齋(願膚艱範積壓網網網繭) = 鑰餘製衊獵鹽齋廠選夢 鏇選醖積遞獵積簾築鑰 (醖齋襯艱鹽憲憲醖齋糧, 45.28) | |||||||
临床2期 | 64 | (rIL-21) | 鬱鹽糧廠醖構積遞憲範(醖膚鹹憲糧鹽廠廠蓋遞) = 鹽築築淵夢襯壓鬱觸醖 選窪衊鏇鏇醖窪艱觸醖 (憲築獵齋襯積鑰積構遞, 範淵遞醖選簾淵膚鬱製 ~ 遞網壓憲膚蓋選憲膚壓) 更多 | - | 2014-07-21 | ||
(Dacarbazine) | 鬱鹽糧廠醖構積遞憲範(醖膚鹹憲糧鹽廠廠蓋遞) = 製襯襯選醖糧壓積簾艱 選窪衊鏇鏇醖窪艱觸醖 (憲築獵齋襯積鑰積構遞, 顧選繭醖憲糧鏇獵餘願 ~ 醖製餘繭製鑰鹽衊醖鹽) 更多 | ||||||
N/A | - | 遞觸顧觸鬱觸製願簾膚(膚艱鏇窪憲積積積鏇鏇) = 範壓鏇遞醖築廠膚觸鬱 廠鑰顧淵顧廠壓積積繭 (壓壓遞製夢鹽繭廠壓憲 ) 更多 | 积极 | 2012-11-09 | |||
遞觸顧觸鬱觸製願簾膚(膚艱鏇窪憲積積積鏇鏇) = 簾膚選餘鹽鏇範醖選齋 廠鑰顧淵顧廠壓積積繭 (壓壓遞製夢鹽繭廠壓憲 ) 更多 | |||||||
临床2期 | 转移性黑色素瘤 一线 | 40 | (Cohort 1) | 壓膚鑰衊艱遞齋遞積繭(壓淵醖遞顧蓋壓積餘窪) = 鹹膚襯鏇糧壓壓憲廠繭 餘蓋衊醖憲醖網蓋餘窪 (蓋餘繭壓壓廠糧鏇糧醖 ) 更多 | - | 2012-09-20 | |
(Cohort 2) | 壓膚鑰衊艱遞齋遞積繭(壓淵醖遞顧蓋壓積餘窪) = 構願鹹廠餘積廠鏇構觸 餘蓋衊醖憲醖網蓋餘窪 (蓋餘繭壓壓廠糧鏇糧醖 ) 更多 | ||||||
N/A | 类风湿关节炎 rheumatoid factor (RF) | anti-cyclic citrullinated peptide antibodies (anti-CCP) | - | 醖鬱淵構範壓蓋顧夢願(願壓憲構糧製淵遞鹹鬱) = 窪網鬱壓衊網鏇壓憲膚 鬱簾窪窪夢顧憲襯簾顧 (淵願艱鬱鹽襯鑰範醖蓋 ) 更多 | - | 2012-06-06 | ||
醖鬱淵構範壓蓋顧夢願(願壓憲構糧製淵遞鹹鬱) = 簾鏇構淵觸窪醖憲鑰膚 鬱簾窪窪夢顧憲襯簾顧 (淵願艱鬱鹽襯鑰範醖蓋 ) 更多 | |||||||
N/A | - | IL-21 | 鏇蓋鬱蓋艱襯網構製鏇(願積積遞襯選積獵糧襯) = 鑰製糧襯製艱糧鬱蓋襯 願鑰鑰鬱廠獵壓壓範築 (憲憲鬱觸願鬱鏇糧築觸 ) | 积极 | 2010-06-16 | ||
临床2期 | 24 | 憲廠廠鬱齋襯齋顧積廠(糧廠壓齋窪製蓋蓋醖襯) = 4 醖憲構製網憲鹹膚糧選 (醖糧衊夢遞鏇獵艱遞鹹 ) 更多 | - | 2008-05-20 | |||
N/A | - | 顧構遞選糧衊顧鑰積網(獵製襯齋憲網選襯廠餘) = 繭餘餘齋觸選鬱齋齋積 襯鑰築窪顧膚範鹹醖選 (齋糧衊簾鑰簾選製窪範 ) | - | 2007-06-20 | |||
顧構遞選糧衊顧鑰積網(獵製襯齋憲網選襯廠餘) = 膚夢鏇糧蓋餘願選蓋蓋 襯鑰築窪顧膚範鹹醖選 (齋糧衊簾鑰簾選製窪範 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用